Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Schedule 13G/A filed for Syndax Pharmaceuticals, Inc. reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 5,581,828.06 shares of Syndax common stock, representing 6.5% of the class as reported for the event date 06/30/2025. The filing shows no sole voting or dispositive power and substantial shared voting power (5,581,718.06) and shared dispositive power (5,581,828.06). The cover exhibits include a joint filing agreement and identification of Goldman Sachs & Co. LLC as a subsidiary of GS Group. The registrants certify the securities are held in the ordinary course of business and not for the purpose of changing control.
Syndax Pharmaceuticals (SNDX) – Form 4 insider activity: Chief Financial Officer Keith A. Goldan purchased 1,226 common shares on 07/31/2025 under the company’s Employee Stock Purchase Plan (ESPP) at an average price of $8.43 per share. The transaction is coded “J,” confirming it is part of a tax-qualified plan rather than an open-market buy.
Following the purchase, Goldan’s direct ownership rises to 93,676 shares. No derivative securities were reported. The filing was submitted on 08/07/2025 and signed by attorney-in-fact Michael A. Metzger.
The acquisition is modest in dollar terms (≈$10 k) but represents incremental insider buying, which can be interpreted as a signal of management confidence. However, the size relative to Goldan’s total stake and SNDX’s share count suggests limited market impact.
Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.
While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.